Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total value of $35,140.90. Following the sale, the director now directly owns 124,490 shares in the company, valued at approximately $3,444,638.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $29.00 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $30.03. The business’s fifty day moving average is $24.08 and its two-hundred day moving average is $22.65. The stock has a market capitalization of $1.36 billion, a P/E ratio of -15.03 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, research analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. Quest Partners LLC increased its position in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. American Century Companies Inc. boosted its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares during the period. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics during the 1st quarter worth approximately $167,000. SG Americas Securities LLC acquired a new stake in Enliven Therapeutics during the 3rd quarter valued at $256,000. Finally, Rhumbline Advisers lifted its holdings in shares of Enliven Therapeutics by 29.9% in the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after purchasing an additional 11,420 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.